While response rates and survival outcomes have been very promising for idecabtagene
vicleucel (ide-cel), a proportion of patients do not respond or relapse early after this B-cell …

Introduction: Ide-cel, a B-cell maturation antigen (BCMA) directed CAR T-cell therapy, has
been FDA approved for the treatment of RRMM after 4 prior lines of therapy. While response …

PURPOSE Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–
directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple …

Background Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation
antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity …

Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy
targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for …

Introduction Outcomes for patients (pts) with relapsed/refractory multiple myeloma (RRMM)
previously treated with immunomodulatory agents, proteasome inhibitors (PIs), and anti …

Objective To understand the experience of patients with relapsed and refractory multiple
myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel), a B-cell maturation antigen …

Introduction Outcomes for patients with relapsed and refractory multiple myeloma (RRMM)
and previous exposure to immunomodulatory agents, proteasome inhibitors (PIs), and anti …

Introduction: Idecabtagene vicleucel (ide-cel) was the first FDA approved BCMA targeted
CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma (RRMM) …

Background: Outcomes remain poor in patients with high-risk relapsed and refractory
multiple myeloma (RRMM) receiving conventional treatments, including immunomodulatory …